Previous reports have confirmed that IL‐6/JAK1/STAT3 pathway is the basic mechanism to promote gefitinib resistance lung cancer.38, 39 In comply with these reports, IL‐6 treatment activated the phosphorylation of JAK1 and STAT3, while left the total amount of JAK1 and STAT3 unchanged (Figure 3A). Here, STAT3 is linked to lung carcinoma.